Arcutis Biotherapeutics Inc (ARQT)
9.30
-0.26
(-2.72%)
USD |
NASDAQ |
Jul 02, 16:00
9.26
-0.04
(-0.43%)
After-Hours: 20:00
Arcutis Biotherapeutics SG&A Expense (Annual): 185.14M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 185.14M |
| December 31, 2022 | 122.12M |
| December 31, 2021 | 60.97M |
| December 31, 2020 | 21.34M |
| Date | Value |
|---|---|
| December 31, 2019 | 6.61M |
| December 31, 2018 | 1.795M |
| December 31, 2017 | 0.695M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
6.61M
Minimum
2019
185.14M
Maximum
2023
79.24M
Average
60.97M
Median
2021
SG&A Expense (Annual) Benchmarks
| Heron Therapeutics Inc | 116.66M |
| Marinus Pharmaceuticals Inc | 61.15M |
| Amgen Inc | 6.179B |
| Pfizer Inc | 14.77B |
| Agios Pharmaceuticals Inc | 119.90M |